Gilead Sciences, Inc.

Gilead Palo Alto, Inc.

Ann Walls Olmsted

Luiz Belardinelli

Toufigh Gordi

Hsiao Lieu

Hsiao Dee Lieu

Myocardial imaging methods are provided that are accomplished by administering doses of a pharmaceutical composition comprising one or more adenosine Areceptor agonists, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.

[object Object]

The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, &#x2014; an adenosine Areceptor agonist &#x2014; to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.

Growing community of inventors

Palo Alto, CA, United States of America

Ann Walls Olmsted